Enlivex Therapeutics (ENLV) 6-K 6 Aug 21 2021 Q2 Condensed Consolidated Financial Statements Financial data

Document And Entity Information

Document And Entity Information	6 Months Ended
	Jun. 30, 2021
Document Information Line Items
Entity Registrant Name	ENLIVEX THERAPEUTICS LTD.
Document Type	6-K
Current Fiscal Year End Date	--12-31
Amendment Flag	false
Entity Central Index Key	0001596812
Document Period End Date	Jun. 30, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Entity File Number	001-36578

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Current Assets
Cash and cash equivalents	$ 12,612	$ 5,673
Short term deposits	10,024	30,034
Marketable securities	67,964
Prepaid expenses and other receivables	1,345	1,164
Restricted cash	90	79
Cash held with respect to CVR Agreement	793	1,171
Total Current Assets	92,828	38,121
Non-Current Assets
Property and equipment, net	1,694	1,481
Other assets	665	756
Total Non-Current Assets	2,359	2,237
TOTAL ASSETS	95,187	40,358
Current Liabilities
Accounts payable trade	558	463
Accrued expenses and other liabilities	3,225	2,738
CVR holders	793	1,171
Total Current Liabilities	4,576	4,372
Non-Current Liabilities
Other long-term Liabilities	405	499
Total Non-Current Liabilities	405	499
Commitments and Contingent Liabilities
TOTAL LIABILITIES	4,981	4,871
SHAREHOLDERS’ EQUITY
Ordinary shares of NIS 0.40 ($0.12) par value: Authorized: 45,000,000 shares as of June 30, 2021 and December 31, 2020; Issued and outstanding:18,306,186 and 14,587,934 as of June 30, 2021 and December 31, 2020;	2,104	1,646
Additional paid in capital	131,663	70,361
Foreign currency translation adjustments	244	977
Accumulated deficit	(43,805)	(37,497)
TOTAL SHAREHOLDERS’ EQUITY	90,206	35,487
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$ 95,187	$ 40,358

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)	Jun. 30, 2021$ / sharesshares	Jun. 30, 2021₪ / sharesshares	Dec. 31, 2020$ / sharesshares	Dec. 31, 2020₪ / sharesshares
Statement of Financial Position [Abstract]
Ordinary shares, par value (in Dollars per share) | $ / shares	$ 0.12		$ 0.12
Ordinary shares of NIS par value (in New Shekels per share) | ₪ / shares		₪ 0.40		₪ 0.40
Ordinary shares, Authorized	45,000,000	45,000,000	45,000,000	45,000,000
Ordinary shares, Issued	18,306,186	18,306,186	14,587,934	14,587,934
Ordinary shares, outstanding	18,306,186	18,306,186	14,587,934	14,587,934

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Income Statement [Abstract]
Revenues
Operating expenses:
Research and development expenses	2,539	1,257	5,036	2,520
General and administrative expenses	1,269	976	2,574	1,609
Total operating expenses	3,808	2,233	7,610	4,129
Operating loss	(3,808)	(2,233)	(7,610)	(4,129)
Other income/(expense), net	700	(808)	1,302	294
Net (loss)	(3,108)	(3,041)	(6,308)	(3,835)
Exchange differences arising from translating financial statements from functional to presentation currency	2,055	888	(733)	(128)
Total other comprehensive income (loss)	2,055	888	(733)	(128)
Total comprehensive (loss)	$ (1,053)	$ (2,153)	$ (7,041)	$ (3,963)
Basic & diluted (loss) per share (in Dollars per share)	$ (0.17)	$ (0.23)	$ (0.36)	$ (0.31)
Weighted average number of shares outstanding (in Shares)	18,305,882	13,441,436	17,397,860	12,419,643

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Cash flows from operating activities
Net (loss)	$ (6,308)	$ (3,835)
Adjustments required to reflect net cash used in operating activities:
Depreciation	239	114
Non-cash operating lease expenses	107	66
Share-based compensation	842	320
Income on marketable securities	(1,583)
Changes in operating asset and liability items:
(Increase) decrease in prepaid expenses and other receivables	(195)	1,444
Increase in accounts payable trade	101	129
Increase (decrease) in accrued expenses and other liabilities	153	(1,071)
Operating lease liabilities	(106)	(62)
Net cash (used in) provided by operating activities	(6,750)	(2,895)
Cash flows from investing activities
Purchase of property and equipment	(472)	(166)
Release (investment) in short-term bank deposits	19,563	(12,000)
Purchases of marketable securities	(85,695)
Proceeds from sales of marketable securities	19,217
Net cash (used in) investing activities	(47,387)	(12,166)
Cash flows from financing activities
Proceeds from issuance of shares and warrants net of $4,455 and $2,294 issuance expenses, respectively	53,174	22,456
Proceeds from exercise of warrants	7,702
Proceeds from exercise of options	42	97
Net cash provided by financing activities	60,918	22,553
Increase in cash and cash equivalents	6,781	7,492
Cash and cash equivalents - beginning of period	7,012	5,524
Exchange rate differences on cash and cash equivalents	(210)	(124)
Cash and cash equivalents - end of period	13,583	12,892
Non-cash transactions:
Warrants issued in settlement of issuance costs to a placement agent	2,095	563
Supplemental disclosures of cash flow information:
Cash paid for taxes
Cash received for interest, net	$ 62	$ 72

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Statement of Cash Flows [Abstract]
warrants net issuance expenses	$ 4,455	$ 2,294

General

General	6 Months Ended
	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GENERAL	NOTE 1 - GENERAL a. Enlivex Therapeutics Ltd. (the “Parent” and, including its consolidated subsidiaries, “we”, “us”, “our” or the “ Company The Company is developing Allocetra TM The Allocetra TM Enlivex Therapeutics R&D Ltd. (“Enlivex R&D” , formerly known as Enlivex Therapeutics Ltd. In January 2015, Bioblast Pharma Inc. was established in the State of Delaware as a wholly owned subsidiary of the Parent. On July 1, 2020 Bioblast Pharma Inc changed its name to Enlivex Therapeutics Inc. The Company’s ordinary shares, NIS 0.40 per share (“Ordinary Shares” or “ordinary shares”), are traded under the symbol “ENLV” on both the Nasdaq Capital Market and the Tel Aviv Stock Exchange. b. Financial Resources The Company devotes substantially all of its efforts toward research and development activities and raising capital to support such activities. The Company’s activities are subject to significant risks and uncertainties, including failing to secure additional funding before the Company achieves sustainable revenues and profit from operations. Research and development activities have required significant capital investment since the Company’s inception. The Company expects that its operations will require additional cash investment to pursue the Company’s research and development activities, including preclinical studies, formulation development, clinical trials and related drug manufacturing. The Company has not generated any revenues or product sales and has not achieved profitable operations or positive cash flow from operations. The Company has incurred net losses since its inception, and, as of June 30, 2021, had an accumulated deficit of $43,805. During the first quarter of 2021 the Company raised a net aggregated amount of $53.2 million in cash from the issuance and sale of 2,848,629 of its ordinary shares and an additional $7.7 million from the exercise of 855,813 warrants and 13,435 options. However, the Company expects to continue to incur losses for at least the next several years and over that period the Company will need to raise additional debt or equity financing or enter into partnerships to fund its development. If the Company is not able to achieve its funding requirements, it may be required to reduce discretionary spending, may not be able to continue the development of its product candidates or may be required to delay its development programs, which could have a material adverse effect on the Company’s ability to achieve its intended business objectives. There can be no assurances that additional financing will be secured or, if secured, will be on favorable terms. The ability of the Company to transition to profitability in the longer term is dependent on developing products and product revenues to support its expenses. The Company’s management and board of directors (the “ Board Based on the Company’s current assessment, the Company does not expect any material impact on its liquidity due to the worldwide spread of the SARS-CoV-2 coronavirus. However, the timelines for the Company’s clinical development programs may be extended due to direct and indirect impacts of the COVID-19 pandemic or new variants of the virus. For example, there has been a delay in recruiting patients for the Company’s randomized, controlled Phase IIb clinical trial of Allocetra TM in patients with severe sepsis due to a lower number of pneumonic septic patients, as a result of the COVID-19 pandemic environment. As previously reported in the Company’s Annual Report on Form 20-F for the year ended December 31, 2020, the Company still expects to obtain interim results from this Phase IIb during 2021 or early 2022 followed by top-line results later in 2022.

Significant Accounting Policies

Significant Accounting Policies	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation These unaudited condensed consolidated financial statements include the accounts of the Company and have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been made. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited annual financial statements and notes thereto included in the Company’s 2020 Annual Report on Form 20-F, as filed with the SEC on April 30, 2021. The results of operations for these interim periods are not necessarily indicative of the operating results for any future period. The December 31, 2020 financial information has been derived from the Company’s audited financial statements. Use of Estimates The preparation of interim financial statements in conformity with U.S. GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts in the consolidated balance sheets and statements of operations, it also requires that management exercise its judgment in applying the Company’s accounting policies. On an ongoing basis, management evaluates its estimates, including estimates related to its stock-based compensation expense and implicit interest rate on new lease liabilities. Significant estimates in these interim financial statements include estimates made for accrued research and development expenses and stock-based compensation expenses. Functional Currency and Translation to The Reporting Currency The functional currency of the Company is the New Israeli Shekel (“NIS”), which is the local currency where the Company operates. The financial statements of the Company were translated into U.S. dollars in accordance with ASC 830, “Foreign Currency Matters”. Accordingly, assets and liabilities were translated from NIS to U.S. dollars using period-end exchange rates, equity items were translated at the exchange rates as of the dates of the respective equity transactions, and income and expense items were translated at average exchange rates during the period. Gains or losses resulting from translation adjustments (which result from translating an entity’s financial statements into U.S. dollars if its functional currency is other than the U.S. dollar) are reported in other comprehensive income (loss) and are reflected in equity, under “accumulated other comprehensive income (loss)”. Balances denominated in, or linked to foreign currencies are stated on the basis of the exchange rates prevailing at the balance sheet date. For foreign currency transactions included in the statement of income, the exchange rates applicable on the relevant transaction dates are used. Transaction gains or losses arising from changes in the exchange rates used in the translation of such balances are carried to financing income or expenses as applicable. 1 U.S. $ = 3.26 NIS and 3.215 NIS as of June 30, 2021 and December 31, 2020, respectively. The U.S. $ increased (decreased) against the NIS (2.22%), 1.4%, (2.78%) and 0.28% in the three and six months ended June 30, 2021 and 2020, respectively. Reclassification of Prior Year Presentation Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations. Recent Accounting Pronouncements Effective January 1, 2021, the Company adopted ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes Effective January 1, 2021, the Company adopted ASU No. 2020-10, Codification Improvements There have been no other material changes to the significant accounting policies previously disclosed in the Company’s Annual Report on Form 20-F for the year ended December 31, 2020. Marketable Securities. The Company has an investment policy that includes guidelines on acceptable investment securities, minimum credit quality, maturity parameters, and concentration and diversification. The Company invests its excess cash primarily in mutual funds that are classified based on the nature of their underlying securities and their availability for use in current operations. The Company’s marketable equity securities are measured at fair value with gains and losses recognized in other income/(expense), net. Net gain recognized on equity securities for the three and six months ended June 30, 2021 was $1,195 and 1,583 thousand of which $ 950 and $1,342 thousand, respectively, were not realized.

Cash, Cash Equivalents and Rest

Cash, Cash Equivalents and Restricted Cash	6 Months Ended
	Jun. 30, 2021
Cash and Cash Equivalents [Abstract]
CASH, CASH EQUIVALENTS AND RESTRICTED CASH	NOTE 3 – CASH, CASH EQUIVALENTS AND RESTRICTED CASH June 30, December 31, (in thousands) 2021 2020 Cash held in banks $ 858 $ 1,173 Bank deposits in U.S.$ (annual average interest rates 0.3% and 0.32%) 11,754 4,500 Total cash and cash equivalents 12,612 5,673 Cash held with respect to CVR Agreement 793 1,171 Short-term restricted cash 90 79 Long-term restricted cash 88 89 Total cash, cash equivalents and restricted cash shown in the statement of cash flows $ 13,583 $ 7,012

Short Term Deposits

Short Term Deposits	6 Months Ended
	Jun. 30, 2020
Debt Disclosure [Abstract]
SHORT TERM DEPOSITS	NOTE 4 – SHORT TERM DEPOSITS June 30, December 31, (in thousands) 2021 2020 Bank deposits in U.S.$ (annual average interest rates 0.61% and 0.6%) 10,024 30,034 Total short-term deposits $ 10,024 $ 30,034

Property and Equipment

Property and Equipment	6 Months Ended
	Jun. 30, 2021
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 5 – PROPERTY AND EQUIPMENT Property and equipment, net consists of the following: June 30, December 31, (in thousands) 2021 2020 Cost: Laboratory equipment $ 1,646 $ 1,256 Computers 190 169 Office furniture & equipment 106 102 Leasehold improvements 739 712 2,681 2,239 Accumulated depreciation: Laboratory equipment 734 588 Computers 108 87 Office furniture & equipment 9 5 Leasehold improvements 136 78 987 758 Depreciated cost $ 1,694 $ 1,481 Depreciation expenses for the three and six months ended June 30, 2021 and 2020 were $122 and $239 thousand and $60 and $114 thousand, respectively.

Other Assets

Other Assets	6 Months Ended
	Jun. 30, 2021
Other Assets [Abstract]
OTHER ASSETS	NOTE 6 – OTHER ASSETS June 30, December 31, (in thousands) 2021 2020 Restricted cash $ 88 $ 89 Long-term prepaid expenses 6 8 Right-of-Use assets, net 571 659 $ 665 $ 756

Accrued Expenses and Other Liab

Accrued Expenses and Other Liabilities	6 Months Ended
	Jun. 30, 2021
Payables and Accruals [Abstract]
ACCRUED EXPENSES AND OTHER LIABILITIES	NOTE 7 – ACCRUED EXPENSES AND OTHER LIABILITIES June 30, December 31, (in thousands) 2021 2020 Vacation, convalescence and bonus accruals $ 411 $ 684 Employees and payroll related 524 352 Short term operating lease liabilities 210 203 Accrued expenses and other 2,080 1,499 $ 3,225 $ 2,738

Leases

Leases	6 Months Ended
	Jun. 30, 2021
Leases [Abstract]
LEASES	NOTE 8 – LEASES The Company is a party to operating leases for its corporate offices, laboratory space and vehicles. The Company’s operating leases have remaining lease terms of up to 4.25 years, some of which include options to extend the leases for up to five years. Six months ended (in thousands) 2021 2020 The components of lease expense were as follows: Operating leases expenses $ 139 $ 93 Supplemental consolidated cash flow information related to operating leases follows: Cash used in operating activities $ 135 $ 88 Non-cash activity: Right of use assets obtained in exchange for new operating lease liabilities $ 29 $ - June 30, December 31, (in thousands) 2021 2020 Supplemental information related to operating leases, including location of amounts reported in the accompanying consolidated balance sheets, follows: Other assets - Right-of-Use assets $ 952 $ 920 Accumulated amortization 381 261 Operating lease Right-of-Use assets, net $ 571 $ 659 Lease liabilities – current - Accounts payable and accrued liabilities $ 210 $ 203 Lease liabilities – noncurrent - Other long-term liabilities 405 499 Total operating lease liabilities $ 615 $ 702 Weighted average remaining lease term in years 3.14 3.64 Weighted average annual discount rate 11.9 % 11.9 % Maturities of operating lease liabilities as of June 30, 2021, were as follows: 2021 (after June 30) $ 130 2022 248 2023 191 2024 94 2025 69 Total undiscounted lease liability $ 732 Less: Imputed interest $ (117 ) Present value of lease liabilities $ 615

Commitments and Contingent Liab

Commitments and Contingent Liabilities	6 Months Ended
	Jun. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENT LIABILITIES	NOTE 9 – COMMITMENTS AND CONTINGENT LIABILITIES The Company is required to pay royalties to the State of Israel (represented by the Israeli Innovation Authority (the “ IIA The gross amount of grants received by the Company from the IIA, including accrued interest as of June 30, 2021, was approximately $7.6 million. As of June 30, 2021, the Company had not paid any royalties to the IIA. In January 2021, the Company submitted a new non-dilutive grant application to the IIA for reimbursement by the IIA of certain expenses associated with its clinical development program of prevention of cytokine storms and organ dysfunction associated with sepsis for a period commencing January 1, 2021 and ending December 31, 2021 (the “ 2021 Sepsis Grant Application

Equity

Equity	6 Months Ended
	Jun. 30, 2021
Equity [Abstract]
EQUITY	NOTE 10 – EQUITY a. On October 22, 2020, the Company entered into an at the market offering agreement (the “ Sales Agreement On February 9, 2021, the Company terminated the prospectus supplement related to the offer and sale of ordinary shares under the Sales Agreement, but the Sales Agreement remains in full force and effect. To that date, the Company had sold an aggregate of 476,983 ordinary shares under the Sales Agreement, having a gross aggregate offering price of $8,557,437 at a gross average price per share of $17.94. Until such time as the Company files with the SEC a new registration statement on Form F-3 and such registration statement becomes effective, the Company may not offer and sell any additional ordinary shares under the Sales Agreement. b. On February 9, 2021, the Company entered into an amended and restated underwriting agreement (the “ Underwriting Agreement Wainwright Offering The Offering closed on February 12, 2021, on which date the Company completed the issuance of 2,296,107 ordinary shares to Wainwright at a price, including the underwriting discount but before other associated fees, of $18.60 per ordinary share, as set forth in the Underwriting Agreement. On February 17, 2021, Wainwright exercised in part its option to purchase additional ordinary shares and purchased 268,205 ordinary shares at a price, including the underwriting discount but before other associated fees, of $18.60 per share, as set forth in the Underwriting Agreement. In accordance with the Underwriting Agreement, the Company paid Wainwright underwriting discounts and commissions equal to 7% of the gross proceeds received by the Company from the sale of the ordinary shares in the Offering, as well as a management fee equal to 1% of the gross proceeds received by the Company from the sale of the ordinary shares in the Offering. In addition, the Company issued to Wainwright 179,501 warrants to purchase ordinary shares of the Company (the “ Underwriter Warrants The Underwriter Warrants were valued at $2,095 thousand using a Black-Scholes model with the following assumptions: estimated weighted average volatility 78.4%; weighted average risk-free interest rate of 0.5%; no dividend; and a weighted average contractual life of 5 years. The net proceeds from the Offering were $47,023 thousand after deducting Wainwright’s fees and other expenses relating to the Offering. c. During February 2021, 855,813 warrants were exercised for an aggregate of 855,813 ordinary shares, which provided the Company with aggregate gross proceeds of $7.7 million. All Company warrants are classified as a component of shareholders’ equity because such warrants are free standing financial instruments that are legally detachable, separately exercisable, do not embody an obligation for the Company to repurchase its own shares, and permit the holders to receive a fixed number of Ordinary Shares upon exercise, requires physical settlement and do not provide any guarantee of value or return. Number of Warrants Exercise price Outstanding January 1, 2021 1,407,683 Issued to placement agent 179,501 $ 25 Exercised (855,813 ) $ 9 Outstanding June 30, 2021 731,371 Comprised as follows: Number of Exercise Price Issuance date Expiration date 27,016 $ 180 March 22, 2016 September 22, 2021 22,750 $ 10 February 26, 2020 February 24, 2025 455,937 $ 9 March 5, 2020 March 5, 2022 46,167 $ 10 March 4, 2020 March 4, 2022 160,727 $ 25 February 12, 2021 February 9, 2026 18,774 $ 25 February 17, 2021 February 9, 2026 731,371

Share-Based Compensation

Share-Based Compensation	6 Months Ended
	Jun. 30, 2021
Share-based Payment Arrangement [Abstract]
SHARE-BASED COMPENSATION	NOTE 11 – SHARE-BASED COMPENSATION a) On May 28, 2021, the Board approved an increase in the number of ordinary shares authorized for issuance to employees, directors and consultants by 1,800,000. As of June 30, 2021, 4,150,704 ordinary shares were authorized for issuance to employees, directors and consultants under the 2019 Equity Incentive Plan, of which 1,610,192 shares were available for future grant. b) The following table contains information concerning options granted under the existing equity incentive plans: Three months ended June 30, 2021 2020 Number of Weighted Number of Weighted Outstanding at beginning of period 1,870,485 $ 5.54 1,694,678 $ 5.63 Granted 310,500 $ 12.57 250,000 $ 3.66 Forfeited and expired (2,685 ) $ 7.38 (31,070 ) $ 6.36 Exercised (375 ) $ 4.68 (35,895 ) $ 2.69 Outstanding at end of period 2,177,925 $ 6.54 1,877,713 $ 5.59 Exercisable at end of period 1,404,809 $ 5.50 1,097,953 $ 5.04 Three months ended June 30, 2021 2020 Number of Weighted Number of Weighted Non-vested at beginning of period 544,163 $ 6.04 575,204 $ 7.05 Granted 310,500 $ 12.57 250,000 $ 3.66 Vested (78,862 ) $ 13.15 (14,374 ) $ 3.63 Forfeited (2,685 ) $ 7.38 (31,070 ) $ 6.38 Non-vested at the end of period 773,116 $ 8.19 779,760 $ 5.85 Six months ended June 30, 2021 2020 Number of Weighted Number of options Weighted Outstanding at beginning of period 1,884,420 $ 5.52 1,625,042 $ 5.72 Granted 310,500 $ 12.57 320,000 $ 3.89 Forfeited and expired (3,185 ) $ 6.96 (31,434 ) $ 6.39 Exercised (13,810 ) $ 2.99 (35,895 ) $ 2.69 Outstanding at end of period 2,177,925 $ 6.54 1,877,713 $ 5.59 Exercisable at end of period 1,404,809 $ 5.50 1,097,953 $ 5.04 Non-vested at beginning of period 601,227 $ 5.93 526,351 $ 7.03 Granted 310,500 $ 12.57 320,000 $ 3.89 Vested (135,426 ) $ 8.22 (35,521 ) $ 3.73 Forfeited (3,185 ) $ 6.96 (31,070 ) $ 6.37 Non-vested at the end of period 773,116 $ 8.19 779,760 $ 5.85 During the three and six months ended June 30, 2021 and 2020, the Company recognized $603 thousand, $778 thousand, $188 thousand and 320 thousand, respectively, of share-based compensation expenses related to stock options. As of June 30, 2021, the total unrecognized estimated compensation cost related to outstanding non-vested stock options was $3,064 thousand which is expected to be recognized over a weighted average period of 1.7 years. c) Set forth below is data regarding the range of exercise prices and remaining contractual life for all options outstanding at June 30, 2021: Exercise Number of options outstanding Remaining Life (in years) Intrinsic Value of No. of options (in thousands) $ 2.69 673,525 4.01 $ 4,183 673,525 $ 3.66 250,000 8.84 1,309 97,223 $ 4.68 59,875 8.75 253 15,250 $ 6.22 658,893 6.55 1,763 498,042 $ 8.19 150,000 8.38 107 37,500 $ 9.02 40,500 9.38 - - $ 10.12 12,126 7.43 - 7,274 $ 12.21 2,421 7.74 - 1,211 $ 21.4 4,585 8.07 - 1,256 $ 12.22 250,000 9.92 27,778 $ 14.00 60,500 9.82 30,250 $ 90.16 15,500 0.15 - 15,500 2,177,925 $ 7,615 1,404,809 d) The following table contains information concerning restricted stock units granted under the existing equity incentive plans: Three months ended June 30, 2021 2020 Number of shares Weighted Number of Weighted grant date fair Nonvested at beginning of period 48,375 $ 14.67 - $ - Granted 13,750 $ 10.28 - $ - Vested -- $ - - $ - Forfeited (2,000 ) $ 14.67 - $ - Nonvested at end of period 60,125 $ 13.67 - $ - Six months ended June 30, 2021 2020 Number of Weighted Number of shares Weighted Nonvested at beginning of period - $ - - $ - Granted 62,125 $ 13.7 - $ - Vested - $ - - $ - Forfeited (2,000 ) $ 14.67 - $ - Nonvested at end of period 60,125 $ 13.67 - $ - The Company estimates the fair value of restricted stock units based on the closing sales price of the Company’s ordinary shares on the date of grant (or the closing bid price, if no sales were reported). During the three and six months ended June 30, 2021 and 2020, the Company recognized $48 thousand, $64 thousand, $0 and $0, respectively, of share-based compensation expense related to restricted stock units. Total share-based compensation expense related to restricted stock units not yet recognized as of June 30, 2021 was $765 thousand, which is expected to be recognized over a weighted average period of 3.65 years. e) The following table summarizes share-based compensation expenses related to grants under the existing equity incentive plans included in the statements of operations: Three months ended June 30, Six months ended June 30, (in thousands) 2021 2020 2021 2020 Research & development $ 358 $ 104 $ 446 $ 200 General & administrative 294 84 396 120 Total $ 652 $ 188 $ 842 $ 320

Fair Value Measurement

Fair Value Measurement	6 Months Ended
	Jun. 30, 2021
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENT	NOTE 12 – FAIR VALUE MEASUREMENT The Company’s financial assets and liabilities measured at fair value on a recurring basis consisted of the following types of instruments as of June 30, 2021 and December 31, 2020: June 30, 2021 (in thousands) Total Level 1 Level 2 Level 3 Cash and cash equivalents $ 12,612 $ 12,612 $ - $ - Short term deposits 10,024 10,024 Marketable securities 67,964 67,964 Restricted cash 178 178 - - Cash held with respect to CVR Agreement 793 793 - - Total financial assets $ 91,571 $ 91,571 $ - $ - December 31, 2020 (in thousands) Total Level 1 Level 2 Level 3 Cash and cash equivalents $ 5,673 $ 5,673 $ - $ - Short term deposits 30,034 30,034 - - Cash held with respect to CVR Agreement 1,171 1,171 - - Restricted cash 168 168 - - Total financial assets $ 37,046 $ 37,046 $ - $ -

Events Subsequent to the Balanc

Events Subsequent to the Balance Sheet Date	6 Months Ended
	Jun. 30, 2021
Subsequent Events [Abstract]
EVENTS SUBSEQUENT TO THE BALANCE SHEET DATE	NOTE 13 – EVENTS SUBSEQUENT TO THE BALANCE SHEET DATE The Company evaluated all events and transactions that occurred subsequent to the balance sheet date and prior to the date on which these unaudited condensed consolidated financial statements were issued, and determined the following subsequent event necessitated disclosure: On July 17, 2021 a single Israeli plaintiff filed a request in the Israeli court of Tel Aviv to approve his lawsuit as an Israeli class action lawsuit against the Company. The claim alleges that the Company did not make various documents filed with the Israel Securities Authority’s submission system appropriately accessible for people with disabilities, specifically that certain PDF filings were not prepared in accordance with certain provisions of the Israeli law and regulations regarding accessibility of documents to the disabled. The plaintiff filed requests for approval of similar class action lawsuits on the same day against 17 other companies whose securities are traded on the Tel-Aviv Stock Exchange. The Company believes that the plaintiff’s claims against the Company are without merit and intends to vigorously defend against them.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation These unaudited condensed consolidated financial statements include the accounts of the Company and have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been made. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited annual financial statements and notes thereto included in the Company’s 2020 Annual Report on Form 20-F, as filed with the SEC on April 30, 2021. The results of operations for these interim periods are not necessarily indicative of the operating results for any future period. The December 31, 2020 financial information has been derived from the Company’s audited financial statements.
Use of Estimates	Use of Estimates The preparation of interim financial statements in conformity with U.S. GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts in the consolidated balance sheets and statements of operations, it also requires that management exercise its judgment in applying the Company’s accounting policies. On an ongoing basis, management evaluates its estimates, including estimates related to its stock-based compensation expense and implicit interest rate on new lease liabilities. Significant estimates in these interim financial statements include estimates made for accrued research and development expenses and stock-based compensation expenses.
Functional Currency and Translation to The Reporting Currency	Functional Currency and Translation to The Reporting Currency The functional currency of the Company is the New Israeli Shekel (“NIS”), which is the local currency where the Company operates. The financial statements of the Company were translated into U.S. dollars in accordance with ASC 830, “Foreign Currency Matters”. Accordingly, assets and liabilities were translated from NIS to U.S. dollars using period-end exchange rates, equity items were translated at the exchange rates as of the dates of the respective equity transactions, and income and expense items were translated at average exchange rates during the period. Gains or losses resulting from translation adjustments (which result from translating an entity’s financial statements into U.S. dollars if its functional currency is other than the U.S. dollar) are reported in other comprehensive income (loss) and are reflected in equity, under “accumulated other comprehensive income (loss)”. Balances denominated in, or linked to foreign currencies are stated on the basis of the exchange rates prevailing at the balance sheet date. For foreign currency transactions included in the statement of income, the exchange rates applicable on the relevant transaction dates are used. Transaction gains or losses arising from changes in the exchange rates used in the translation of such balances are carried to financing income or expenses as applicable. 1 U.S. $ = 3.26 NIS and 3.215 NIS as of June 30, 2021 and December 31, 2020, respectively. The U.S. $ increased (decreased) against the NIS (2.22%), 1.4%, (2.78%) and 0.28% in the three and six months ended June 30, 2021 and 2020, respectively.
Reclassification of Prior Year Presentation	Reclassification of Prior Year Presentation Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Effective January 1, 2021, the Company adopted ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes Effective January 1, 2021, the Company adopted ASU No. 2020-10, Codification Improvements There have been no other material changes to the significant accounting policies previously disclosed in the Company’s Annual Report on Form 20-F for the year ended December 31, 2020.
Marketable Securities	Marketable Securities. The Company has an investment policy that includes guidelines on acceptable investment securities, minimum credit quality, maturity parameters, and concentration and diversification. The Company invests its excess cash primarily in mutual funds that are classified based on the nature of their underlying securities and their availability for use in current operations. The Company’s marketable equity securities are measured at fair value with gains and losses recognized in other income/(expense), net. Net gain recognized on equity securities for the three and six months ended June 30, 2021 was $1,195 and 1,583 thousand of which $ 950 and $1,342 thousand, respectively, were not realized.

Cash, Cash Equivalents and Re_2

Cash, Cash Equivalents and Restricted Cash (Tables)	6 Months Ended
	Jun. 30, 2021
Cash and Cash Equivalents [Abstract]
Schedule of cash and cash equivalents and restricted cash	June 30, December 31, (in thousands) 2021 2020 Cash held in banks $ 858 $ 1,173 Bank deposits in U.S.$ (annual average interest rates 0.3% and 0.32%) 11,754 4,500 Total cash and cash equivalents 12,612 5,673 Cash held with respect to CVR Agreement 793 1,171 Short-term restricted cash 90 79 Long-term restricted cash 88 89 Total cash, cash equivalents and restricted cash shown in the statement of cash flows $ 13,583 $ 7,012

Short Term Deposits (Tables)

Short Term Deposits (Tables)	6 Months Ended
	Jun. 30, 2020
Debt Disclosure [Abstract]
Schedule of short term deposits	June 30, December 31, (in thousands) 2021 2020 Bank deposits in U.S.$ (annual average interest rates 0.61% and 0.6%) 10,024 30,034 Total short-term deposits $ 10,024 $ 30,034

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2021
Property, Plant and Equipment [Abstract]
Schedule of property and equipment	June 30, December 31, (in thousands) 2021 2020 Cost: Laboratory equipment $ 1,646 $ 1,256 Computers 190 169 Office furniture & equipment 106 102 Leasehold improvements 739 712 2,681 2,239 Accumulated depreciation: Laboratory equipment 734 588 Computers 108 87 Office furniture & equipment 9 5 Leasehold improvements 136 78 987 758 Depreciated cost $ 1,694 $ 1,481

Other Assets (Tables)

Other Assets (Tables)	6 Months Ended
	Jun. 30, 2021
Disclosure Text Block Supplement [Abstract]
Schedule of other assets	June 30, December 31, (in thousands) 2021 2020 Restricted cash $ 88 $ 89 Long-term prepaid expenses 6 8 Right-of-Use assets, net 571 659 $ 665 $ 756

Accrued Expenses and Other Li_2

Accrued Expenses and Other Liabilities (Tables)	6 Months Ended
	Jun. 30, 2021
Payables and Accruals [Abstract]
Schedule of accrued expenses and other liabilities	June 30, December 31, (in thousands) 2021 2020 Vacation, convalescence and bonus accruals $ 411 $ 684 Employees and payroll related 524 352 Short term operating lease liabilities 210 203 Accrued expenses and other 2,080 1,499 $ 3,225 $ 2,738

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2021
Leases [Abstract]
Schedule of operating lease	Six months ended (in thousands) 2021 2020 The components of lease expense were as follows: Operating leases expenses $ 139 $ 93 Supplemental consolidated cash flow information related to operating leases follows: Cash used in operating activities $ 135 $ 88 Non-cash activity: Right of use assets obtained in exchange for new operating lease liabilities $ 29 $ -
Schedule of operating lease related activities	June 30, December 31, (in thousands) 2021 2020 Supplemental information related to operating leases, including location of amounts reported in the accompanying consolidated balance sheets, follows: Other assets - Right-of-Use assets $ 952 $ 920 Accumulated amortization 381 261 Operating lease Right-of-Use assets, net $ 571 $ 659 Lease liabilities – current - Accounts payable and accrued liabilities $ 210 $ 203 Lease liabilities – noncurrent - Other long-term liabilities 405 499 Total operating lease liabilities $ 615 $ 702 Weighted average remaining lease term in years 3.14 3.64 Weighted average annual discount rate 11.9 % 11.9 %
Schedule of maturities of operating lease liabilities	Maturities of operating lease liabilities as of June 30, 2021, were as follows: 2021 (after June 30) $ 130 2022 248 2023 191 2024 94 2025 69 Total undiscounted lease liability $ 732 Less: Imputed interest $ (117 ) Present value of lease liabilities $ 615

Equity (Tables)

Equity (Tables)	6 Months Ended
	Jun. 30, 2021
Disclosure Of Equity Explanatory [Abstract]
Schedule of changes in number of shares warrants	Number of Warrants Exercise price Outstanding January 1, 2021 1,407,683 Issued to placement agent 179,501 $ 25 Exercised (855,813 ) $ 9 Outstanding June 30, 2021 731,371
Schedule of changes in exercisable ordinary shares warrants	Comprised as follows: Number of Exercise Price Issuance date Expiration date 27,016 $ 180 March 22, 2016 September 22, 2021 22,750 $ 10 February 26, 2020 February 24, 2025 455,937 $ 9 March 5, 2020 March 5, 2022 46,167 $ 10 March 4, 2020 March 4, 2022 160,727 $ 25 February 12, 2021 February 9, 2026 18,774 $ 25 February 17, 2021 February 9, 2026 731,371

Share-Based Compensation (Table

Share-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2021
Share-based Payment Arrangement [Abstract]
Schedule of employees and directors stock options	Three months ended June 30, 2021 2020 Number of Weighted Number of Weighted Outstanding at beginning of period 1,870,485 $ 5.54 1,694,678 $ 5.63 Granted 310,500 $ 12.57 250,000 $ 3.66 Forfeited and expired (2,685 ) $ 7.38 (31,070 ) $ 6.36 Exercised (375 ) $ 4.68 (35,895 ) $ 2.69 Outstanding at end of period 2,177,925 $ 6.54 1,877,713 $ 5.59 Exercisable at end of period 1,404,809 $ 5.50 1,097,953 $ 5.04 Three months ended June 30, 2021 2020 Number of Weighted Number of Weighted Non-vested at beginning of period 544,163 $ 6.04 575,204 $ 7.05 Granted 310,500 $ 12.57 250,000 $ 3.66 Vested (78,862 ) $ 13.15 (14,374 ) $ 3.63 Forfeited (2,685 ) $ 7.38 (31,070 ) $ 6.38 Non-vested at the end of period 773,116 $ 8.19 779,760 $ 5.85 Six months ended June 30, 2021 2020 Number of Weighted Number of options Weighted Outstanding at beginning of period 1,884,420 $ 5.52 1,625,042 $ 5.72 Granted 310,500 $ 12.57 320,000 $ 3.89 Forfeited and expired (3,185 ) $ 6.96 (31,434 ) $ 6.39 Exercised (13,810 ) $ 2.99 (35,895 ) $ 2.69 Outstanding at end of period 2,177,925 $ 6.54 1,877,713 $ 5.59 Exercisable at end of period 1,404,809 $ 5.50 1,097,953 $ 5.04 Non-vested at beginning of period 601,227 $ 5.93 526,351 $ 7.03 Granted 310,500 $ 12.57 320,000 $ 3.89 Vested (135,426 ) $ 8.22 (35,521 ) $ 3.73 Forfeited (3,185 ) $ 6.96 (31,070 ) $ 6.37 Non-vested at the end of period 773,116 $ 8.19 779,760 $ 5.85
Schedule of exercise prices and remaining contractual life	Exercise Number of options outstanding Remaining Life (in years) Intrinsic Value of No. of options (in thousands) $ 2.69 673,525 4.01 $ 4,183 673,525 $ 3.66 250,000 8.84 1,309 97,223 $ 4.68 59,875 8.75 253 15,250 $ 6.22 658,893 6.55 1,763 498,042 $ 8.19 150,000 8.38 107 37,500 $ 9.02 40,500 9.38 - - $ 10.12 12,126 7.43 - 7,274 $ 12.21 2,421 7.74 - 1,211 $ 21.4 4,585 8.07 - 1,256 $ 12.22 250,000 9.92 27,778 $ 14.00 60,500 9.82 30,250 $ 90.16 15,500 0.15 - 15,500 2,177,925 $ 7,615 1,404,809
Schedule of consultants stock options	Three months ended June 30, 2021 2020 Number of shares Weighted Number of Weighted grant date fair Nonvested at beginning of period 48,375 $ 14.67 - $ - Granted 13,750 $ 10.28 - $ - Vested -- $ - - $ - Forfeited (2,000 ) $ 14.67 - $ - Nonvested at end of period 60,125 $ 13.67 - $ - Six months ended June 30, 2021 2020 Number of Weighted Number of shares Weighted Nonvested at beginning of period - $ - - $ - Granted 62,125 $ 13.7 - $ - Vested - $ - - $ - Forfeited (2,000 ) $ 14.67 - $ - Nonvested at end of period 60,125 $ 13.67 - $ -
Schedule of share-based compensation expenses related to grants under the equity incentive plan	Three months ended June 30, Six months ended June 30, (in thousands) 2021 2020 2021 2020 Research & development $ 358 $ 104 $ 446 $ 200 General & administrative 294 84 396 120 Total $ 652 $ 188 $ 842 $ 320

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	6 Months Ended
	Jun. 30, 2021
Fair Value Disclosures [Abstract]
Schedule of financial assets and liabilities measured at fair value on a recurring basis	June 30, 2021 (in thousands) Total Level 1 Level 2 Level 3 Cash and cash equivalents $ 12,612 $ 12,612 $ - $ - Short term deposits 10,024 10,024 Marketable securities 67,964 67,964 Restricted cash 178 178 - - Cash held with respect to CVR Agreement 793 793 - - Total financial assets $ 91,571 $ 91,571 $ - $ - December 31, 2020 (in thousands) Total Level 1 Level 2 Level 3 Cash and cash equivalents $ 5,673 $ 5,673 $ - $ - Short term deposits 30,034 30,034 - - Cash held with respect to CVR Agreement 1,171 1,171 - - Restricted cash 168 168 - - Total financial assets $ 37,046 $ 37,046 $ - $ -

General (Details)

General (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2021USD ($)shares	Jun. 30, 2021USD ($)	Jun. 30, 2021₪ / shares	Feb. 28, 2021shares	Dec. 31, 2020USD ($)
General (Textual)
Aggregate of ordinary shares | ₪ / shares			₪ 40
Accumulated deficit | $		$ (43,805)			$ (37,497)
Cash | $	$ 53,200
Issuance and sale of stock | shares	2,848,629
Additional amount | $	$ 7,700
Warrant exercisable | shares	855,813			855,813
Number of shares option | shares	13,435

Significant Accounting Polici_2

Significant Accounting Policies (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021USD ($)	Jun. 30, 2020	Jun. 30, 2021USD ($)	Jun. 30, 2020	Dec. 31, 2020
Significant Accounting Policies (Details) [Line Items]
Net gain recognized (in Dollars)	$ 1,195		$ 1,583
Equity Securities [Member]
Significant Accounting Policies (Details) [Line Items]
Net gain recognized (in Dollars)	$ 950		$ 1,342
NIS [Member]
Significant Accounting Policies (Details) [Line Items]
Exchange rate for 1 $ = NIS	3.26		3.26		3.215
Increase (decrease) of the U.S. $ against the NIS	(2.22%)	2.78%	(1.40%)	(0.28%)

Cash, Cash Equivalents and Re_3

Cash, Cash Equivalents and Restricted Cash (Details) - Schedule of cash and cash equivalents and restricted cash - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020	Jun. 30, 2020	Dec. 31, 2019
Schedule of cash and cash equivalents and restricted cash [Abstract]
Cash held in banks	$ 858	$ 1,173
Bank deposits in U.S.$ (annual average interest rates 0.3% and 0.32%)	11,754	4,500
Total cash and cash equivalents	12,612	5,673
Cash held with respect to CVR Agreement	793	1,171
Short-term restricted cash	90	79
Long-term restricted cash	88	89
Total cash, cash equivalents and restricted cash shown in the statement of cash flows	$ 13,583	$ 7,012	$ 12,892	$ 5,524

Cash, Cash Equivalents and Re_4

Cash, Cash Equivalents and Restricted Cash (Details) - Schedule of cash and cash equivalents and restricted cash (Parentheticals)	Jun. 30, 2021	Dec. 31, 2020
Schedule of cash and cash equivalents and restricted cash [Abstract]
Annual average interest rates	0.30%	0.32%

Short Term Deposits (Details) -

Short Term Deposits (Details) - Schedule of short term deposits - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Schedule of short term deposits [Abstract]
Bank deposits in U.S.$ (annual average interest rates 0.61% and 0.6%)	$ 10,024	$ 30,034
Total short-term deposits	$ 10,024	$ 30,034

Property and Equipment (Details

Property and Equipment (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Property, Plant and Equipment [Abstract]
Depreciation expenses	$ 122	$ 60	$ 239	$ 114

Property and Equipment (Detai_2

Property and Equipment (Details) - Schedule of property and equipment - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Cost	$ 2,681	$ 2,239
Total accumulated depreciation	987	758
Depreciated cost	1,694	1,481
Laboratory equipment [Member]
Property, Plant and Equipment [Line Items]
Cost	1,646	1,256
Total accumulated depreciation	734	588
Computers [Member]
Property, Plant and Equipment [Line Items]
Cost	190	169
Total accumulated depreciation	108	87
Office furniture & equipment [Member]
Property, Plant and Equipment [Line Items]
Cost	106	102
Total accumulated depreciation	9	5
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Cost	739	712
Total accumulated depreciation	$ 136	$ 78

Other Assets (Details) - Schedu

Other Assets (Details) - Schedule of other assets - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Schedule of other assets [Abstract]
Restricted cash	$ 88	$ 89
Long-term prepaid expenses	6	8
Right-of-Use assets, net	571	659
Total	$ 665	$ 756

Accrued Expenses and Other Li_3

Accrued Expenses and Other Liabilities (Details) - Schedule of accrued expenses and other liabilities - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Schedule of accrued expenses and other liabilities [Abstract]
Vacation, convalescence and bonus accruals	$ 411	$ 684
Employees and payroll related	524	352
Short term operating lease liabilities	210	203
Accrued expenses and other	2,080	1,499
Accrued expenses and other liabilities, Total	$ 3,225	$ 2,738

Leases (Details)

Leases (Details)	6 Months Ended
	Jun. 30, 2021
Disclosure Text Block [Abstract]
Operating lease remaining term	4 years 3 months

Leases (Details) - Schedule of

Leases (Details) - Schedule of operating lease - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
The components of lease expense were as follows:
Operating leases expenses	$ 139	$ 93
Supplemental consolidated cash flow information related to operating leases follows:
Cash used in operating activities	135	88
Non-cash activity:
Right of use assets obtained in exchange for new operating lease liabilities	$ 29

Leases (Details) - Schedule o_2

Leases (Details) - Schedule of operating lease related activities - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Schedule of operating lease related activities [Abstract]
Other assets - Right-of-Use assets	$ 952	$ 920
Accumulated amortization	381	261
Operating lease Right-of-Use assets, net	571	659
Lease liabilities – current - Accounts payable and accrued liabilities	210	203
Lease liabilities – noncurrent - Other long-term liabilities	405	499
Total operating lease liabilities	$ 615	$ 702
Weighted average remaining lease term in years	3 years 1 month 20 days	3 years 7 months 20 days
Weighted average annual discount rate	11.90%	11.90%

Leases (Details) - Schedule o_3

Leases (Details) - Schedule of maturities of operating lease liabilities $ in Thousands	Jun. 30, 2021USD ($)
Schedule of maturities of operating lease liabilities [Abstract]
2021 (after June 30)	$ 130
2022	248
2023	191
2024	94
2025	69
Total undiscounted lease liability	732
Less: Imputed interest	(117)
Present value of lease liabilities	$ 615

Commitments and Contingent Li_2

Commitments and Contingent Liabilities (Details) $ in Thousands, ₪ in Millions	6 Months Ended
	Jun. 30, 2021USD ($)	May 31, 2021USD ($)	May 31, 2021ILS (₪)
Commitments and Contingent Liabilities (Details) [Line Items]
Percentage of grants	100.00%
Interest Expense (in Dollars)	$ 7,600
Other Commitments		$ 1,160	₪ 3.8
Minimum [Member]
Commitments and Contingent Liabilities (Details) [Line Items]
Percentage of royalties in sales	3.00%
Maximum [Member]
Commitments and Contingent Liabilities (Details) [Line Items]
Percentage of royalties in sales	5.00%

Equity (Details)

Equity (Details) - USD ($)	Feb. 12, 2021	Feb. 09, 2021	Feb. 28, 2021	Feb. 17, 2021	Oct. 22, 2020	Jun. 30, 2021	Mar. 31, 2021
Equity (Details) [Line Items]
Aggregate of offering price (in Dollars)		$ 8,557,437
Gross proceed (in Dollars)			$ 7,700,000
Purchase of ordinary shares		476,983	855,813
Gross average price per share (in Dollars per share)		$ 17.94
Purchase of additional shares				268,205
Sale of stock price per share (in Dollars per share)				$ 18.60
Underwriting discount percentage						7.00%
Gross proceed percentage						1.00%
Warrant purchased						179,501
Warrant exercisable						5 years
Exercise price per share (in Dollars per share)						$ 25
Various expenses (in Dollars)						$ 126,000
Net proceeds offering (in Dollars)						47,023,000
Warrant exercisable			855,813				855,813
Sales Agreement [Member]
Equity (Details) [Line Items]
Aggregate of offering price (in Dollars)					$ 25,000,000
Sales agent commission, percentage					3.00%
Gross proceed (in Dollars)		$ 6,339,095
Purchase of ordinary shares		284,317
Gross average price per share (in Dollars per share)		$ 22.29
Issuance expenses (in Dollars)		$ 192,000
Wainwright & Co., LLC [Member]
Equity (Details) [Line Items]
Purchase of ordinary shares		2,296,107
Purchase of additional shares		344,416
Sale of stock price per share (in Dollars per share)	$ 18.60	$ 20
Issuance of ordinary shares	2,296,107
Warrant [Member]
Equity (Details) [Line Items]
Warrant value (in Dollars)						$ 2,095,000
Weighted average volatility rate						78.40%
Weighted average risk free interest rate						0.50%
Weighted average contractual expected life						5 years

Equity (Details) - Schedule of

Equity (Details) - Schedule of changes in number of shares warrants	6 Months Ended
	Jun. 30, 2021$ / sharesshares
Schedule of changes in number of shares warrants [Abstract]
Number of Warrants, Outstanding Beginning	1,407,683
Number of Warrants, Issued to placement agent	179,501
Exercise price per share, Issued to placement agent (in Dollars per share) | $ / shares	$ 25
Number of Warrants, Exercised	(855,813)
Exercise price per share, Exercised (in Dollars per share) | $ / shares	$ 9
Number of Warrants, Outstanding Ending	731,371

Equity (Details) - Schedule o_2

Equity (Details) - Schedule of changes in exercisable ordinary shares warrants	6 Months Ended
	Jun. 30, 2021$ / sharesshares
Class of Warrant or Right [Line Items]
Number of Warrants | shares	731,371
Exercise price per share | $ / shares	$ 25
Exercise Price 180 [Member]
Class of Warrant or Right [Line Items]
Number of Warrants | shares	27,016
Exercise price per share | $ / shares	$ 180
Issuance date	Mar. 22, 2016
Expiration date	Sep. 22, 2021
Exercise Price 10 [Member]
Class of Warrant or Right [Line Items]
Number of Warrants | shares	22,750
Exercise price per share | $ / shares	$ 10
Issuance date	Feb. 26, 2020
Expiration date	Feb. 24, 2025
Exercise Price 9 [Member]
Class of Warrant or Right [Line Items]
Number of Warrants | shares	455,937
Exercise price per share | $ / shares	$ 9
Issuance date	Mar. 5, 2020
Expiration date	Mar. 5, 2022
Exercise Price 10 [Member]
Class of Warrant or Right [Line Items]
Number of Warrants | shares	46,167
Exercise price per share | $ / shares	$ 10
Issuance date	Mar. 4, 2020
Expiration date	Mar. 4, 2022
Exercise Price 25 [Member]
Class of Warrant or Right [Line Items]
Number of Warrants | shares	160,727
Exercise price per share | $ / shares	$ 25
Issuance date	Feb. 12, 2021
Expiration date	Feb. 9, 2026
Exercise Price 25 [Member]
Class of Warrant or Right [Line Items]
Number of Warrants | shares	18,774
Exercise price per share | $ / shares	$ 25
Issuance date	Feb. 17, 2021
Expiration date	Feb. 9, 2026

Share-Based Compensation (Detai

Share-Based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	May 28, 2021
Share-Based Compensation (Details) [Line Items]
Ordinary shares authorized (in Shares)	4,150,704		4,150,704		1,800,000
Share-based compensation expenses	$ 603	$ 778	$ 188	$ 320
Employees' Stock Option [Member]
Share-Based Compensation (Details) [Line Items]
Total unrecognized estimated compensation cost			$ 3,064
Weighted average period			1 year 8 months 12 days
Consultants' stock options [Member]
Share-Based Compensation (Details) [Line Items]
Total unrecognized estimated compensation cost			$ 765
Weighted average period			3 years 7 months 24 days
2019 Equity Incentive Plan [Member]
Share-Based Compensation (Details) [Line Items]
Future grant share (in Shares)	1,610,192		1,610,192
Restricted Stock [Member]
Share-Based Compensation (Details) [Line Items]
Share-based compensation expenses	$ 48	$ 64	$ 0	$ 0

Share-Based Compensation (Det_2

Share-Based Compensation (Details) - Schedule of employees and directors stock options - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Schedule of employees and directors stock options [Abstract]
Number of options, Outstanding at beginning of period	1,870,485	1,694,678	1,884,420	1,625,042
Weighted average exercise price, Outstanding at beginning of period	$ 5.54	$ 5.63	$ 5.52	$ 5.72
Number of options, Granted	310,500	250,000	310,500	320,000
Weighted average exercise price, Granted	$ 12.57	$ 3.66	$ 12.57	$ 3.89
Number of options, Forfeited and expired	(2,685)	(31,070)	(3,185)	(31,434)
Weighted average exercise price, Forfeited and expired	$ 7.38	$ 6.36	$ 6.96	$ 6.39
Number of options, Exercised	(375)	(35,895)	(13,810)	(35,895)
Weighted average exercise price, Exercised	$ 4.68	$ 2.69	$ 2.99	$ 2.69
Number of options, Outstanding at end of period	2,177,925	1,877,713	2,177,925	1,877,713
Weighted average exercise price, Outstanding at end of period	$ 6.54	$ 5.59	$ 6.54	$ 5.59
Number of options, Exercisable at end of period	1,404,809	1,097,953	1,404,809	1,097,953
Weighted average exercise price, Exercisable at end of period	$ 5.50	$ 5.04	$ 5.50	$ 5.04
Number of options, Non-vested at beginning of period	544,163	575,204	601,227	526,351
Weighted average exercise price, Non-vested at beginning of period	$ 6.04	$ 7.05	$ 5.93	$ 7.03
Number of options, Granted	310,500	250,000	310,500	320,000
Weighted average exercise price, Granted	$ 12.57	$ 3.66	$ 12.57	$ 3.89
Number of options, Vested	(78,862)	(14,374)	(135,426)	(35,521)
Weighted average exercise price, Vested	$ 13.15	$ 3.63	$ 8.22	$ 3.73
Number of options, Forfeited	(2,685)	(31,070)	(3,185)	(31,070)
Weighted average exercise price, Forfeited	$ 7.38	$ 6.38	$ 6.96	$ 6.37
Number of options, Non-vested at the end of period	773,116	779,760	773,116	779,760
Weighted average exercise price, Non-vested at the end of period	$ 8.19	$ 5.85	$ 8.19	$ 5.85

Share-Based Compensation (Det_3

Share-Based Compensation (Details) - Schedule of exercise prices and remaining contractual life $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2021USD ($)$ / sharesshares
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of options outstanding	2,177,925
Intrinsic Value of Options Outstanding (in Dollars) | $	$ 7,615
No. of options exercisable	1,404,809
Exercise Price One [Member] | Option [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 2.69
Number of options outstanding	673,525
Remaining contractual Life (in years)	4 years 3 days
Intrinsic Value of Options Outstanding (in Dollars) | $	$ 4,183
No. of options exercisable	673,525
Exercise Price Two [Member] | Option [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 3.66
Number of options outstanding	250,000
Remaining contractual Life (in years)	8 years 10 months 2 days
Intrinsic Value of Options Outstanding (in Dollars) | $	$ 1,309
No. of options exercisable	97,223
Exercise Price Three [Member] | Option [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 4.68
Number of options outstanding	59,875
Remaining contractual Life (in years)	8 years 9 months
Intrinsic Value of Options Outstanding (in Dollars) | $	$ 253
No. of options exercisable	15,250
Exercise Price Four [Member] | Option [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 6.22
Number of options outstanding	658,893
Remaining contractual Life (in years)	6 years 6 months 18 days
Intrinsic Value of Options Outstanding (in Dollars) | $	$ 1,763
No. of options exercisable	498,042
Exercise Price Five [Member] | Option [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 8.19
Number of options outstanding	150,000
Remaining contractual Life (in years)	8 years 4 months 17 days
Intrinsic Value of Options Outstanding (in Dollars) | $	$ 107
No. of options exercisable	37,500
Exercise Price Six [Member] | Option [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 9.02
Number of options outstanding	40,500
Remaining contractual Life (in years)	9 years 4 months 17 days
Intrinsic Value of Options Outstanding (in Dollars) | $
No. of options exercisable
Exercise Price Seven [Member] | Option [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 10.12
Number of options outstanding	12,126
Remaining contractual Life (in years)	7 years 5 months 4 days
Intrinsic Value of Options Outstanding (in Dollars) | $
No. of options exercisable	7,274
Exercise Price Eight [Member] | Option [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 12.21
Number of options outstanding	2,421
Remaining contractual Life (in years)	7 years 8 months 26 days
Intrinsic Value of Options Outstanding (in Dollars) | $
No. of options exercisable	1,211
Exercise Price Nine [Member] | Option [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 21.4
Number of options outstanding	4,585
Remaining contractual Life (in years)	8 years 25 days
Intrinsic Value of Options Outstanding (in Dollars) | $
No. of options exercisable	1,256
Exercise Price Ten [Member] | Option [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 12.22
Number of options outstanding	250,000
Remaining contractual Life (in years)	9 years 11 months 1 day
No. of options exercisable	27,778
Exercise Price Eleven [Member] | Option [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 14
Number of options outstanding	60,500
Remaining contractual Life (in years)	9 years 9 months 25 days
No. of options exercisable	30,250
Exercise Price Twelve [Member] | Option [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 90.16
Number of options outstanding	15,500
Remaining contractual Life (in years)	1 month 24 days
Intrinsic Value of Options Outstanding (in Dollars) | $
No. of options exercisable	15,500

Share-Based Compensation (Det_4

Share-Based Compensation (Details) - Schedule of consultants stock options - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Schedule of consultants stock options [Abstract]
Number of shares, Nonvested at beginning of period	48,375
Weighted average grant date fair value, Nonvested at beginning of period	$ 14.67
Number of shares, Granted	13,750		62,125
Weighted average grant date fair value, Granted	$ 10.28		$ 13.7
Number of shares, Vested
Weighted average grant date fair value, Vested
Number of shares, Forfeited	(2,000)		(2,000)
Weighted average grant date fair value, Forfeited	$ 14.67		$ 14.67
Number of shares, Nonvested at end of period	60,125		60,125
Weighted average grant date fair value, Nonvested at end of period	$ 13.67		$ 13.67

Share-Based Compensation (Det_5

Share-Based Compensation (Details) - Schedule of share-based compensation expenses related to grants under the equity incentive plan - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	$ 652	$ 188	$ 842	$ 320
Research & development [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	358	104	446	200
General & administrative [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	$ 294	$ 84	$ 396	$ 120

Fair Value Measurement (Details

Fair Value Measurement (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Fair Value Measurement (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis [Line Items]
Cash and cash equivalents	$ 12,612	$ 5,673
Short term deposits	10,024	30,034
Marketable securities	67,964
Restricted cash	178	168
Cash held with respect to CVR Agreement	793	1,171
Total financial assets	91,571	37,046
Level 1 [Member]
Fair Value Measurement (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis [Line Items]
Cash and cash equivalents	12,612	5,673
Short term deposits	10,024	30,034
Marketable securities	67,964
Restricted cash	178	168
Cash held with respect to CVR Agreement	793	1,171
Total financial assets	91,571	37,046
Level 2 [Member]
Fair Value Measurement (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis [Line Items]
Cash and cash equivalents
Short term deposits
Restricted cash
Cash held with respect to CVR Agreement
Total financial assets
Level 3 [Member]
Fair Value Measurement (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis [Line Items]
Cash and cash equivalents
Short term deposits
Restricted cash
Cash held with respect to CVR Agreement
Total financial assets